• No results found

Targeting interleukin-6 in rheumatoid arthritis

N/A
N/A
Protected

Academic year: 2019

Share "Targeting interleukin-6 in rheumatoid arthritis"

Copied!
47
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1: Interleukin-6 blocking agents other than intravenous tocilizumab currently under development
Table 2: Percentage of patients who met the American College of Rheumatology (ACR) 20, 50 and 70 improvement criteria based
Table 3: The main safety profiles of tocilizumab as reported in phase III randomised controlled trials
Table 4: Laboratory abnormalities secondary to tocilizumab treatment as reported in Phase III randomised controlled trials

References

Related documents

• Citizen participation tool: municipalities are able to contact cyclists directly and vice versa. Cyclists feel that their concerns are

This report deals with the Divisions of Government and Political Theory and Interna- tional Relations in the School of Political Sciences in the Faculty of Social Studies at

prevention early intervention and diversion services to minors served by Cupertino Union School District CUSD and the

Different databases used for this course recommendation they are: Former student base- collection of data which is collected using data mining technique

The material substrate cotton makes the fabrication more easy in an handmade embroidery and also makes the antenna to work in higher frequency range and the stainless steel

Our results showed that activation of ER stress by tunica- mycin counteracted the inhibitory effects of GB on cTnI and cTnT levels and apoptosis index, verifying our conclusion

We successfully developed an exposure–response model describing the extent and time course of weight loss in response to sibutramine treatment. We did this by utilizing

The rate of transition of the fuel composition to the equilibrium in considered mode of processing was determined for different starting isotopic compositions of plutonium